| Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (NCT03399773) | Fred Hutchinson Cancer Center | 2022-05-10 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II (NCT03941769) | M.D. Anderson Cancer Center | 2020-09-29 |
| Genomics Study in CML Patients With Ponatinib Treatment (NCT06945146) | Dong-Wook Kim | 2020-09-01 |
| A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia (NCT04694820) | Thomas Jefferson University | 2020-06-05 |
| DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer (NCT04282343) | Barbara Ann Karmanos Cancer Institute | 2020-02-25 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant (NCT03267186) | Andrew Rezvani | 2017-09-12 |
| Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia (NCT03195010) | Fred Hutchinson Cancer Center | 2017-06-09 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant (NCT03128359) | City of Hope Medical Center | 2017-05-30 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (NCT02730195) | Emory University | 2016-05-01 |
| Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor (NCT02734823) | University of Southern California | 2016-03-01 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children (NCT01858740) | Fred Hutchinson Cancer Center | 2014-04-10 |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors (NCT01751425) | M.D. Anderson Cancer Center | 2013-07-24 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies (NCT01789255) | National Cancer Institute (NCI) | 2013-06-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia (NCT01670084) | Mayo Clinic | 2012-12-01 |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate (NCT01426334) | National Cancer Institute (NCI) | 2011-09-01 |
| Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant (NCT00796068) | Fred Hutchinson Cancer Center | 2009-02-24 |
| Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML (NCT00702403) | Fred Hutchinson Cancer Center | 2008-08-14 |
| Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases (NCT00351975) | National Cancer Institute (NCI) | 2006-06-01 |
| Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia (NCT01445080) | National Cancer Institute (NCI) | 2006-05-30 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia (NCT00101088) | National Cancer Institute (NCI) | 2005-04-01 |
| Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant (NCT00096161) | Fred Hutchinson Cancer Center | 2003-05-01 |
| Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (NCT00060372) | National Cancer Institute (NCI) | 2003-04-01 |
| Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia (NCT00054431) | National Cancer Institute (NCI) | 2003-01-01 |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia (NCT00049192) | National Cancer Institute (NCI) | 2002-11-01 |
| Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia (NCT00030394) | National Cancer Institute (NCI) | 2002-09-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib (NCT00036738) | Fred Hutchinson Cancer Center | 2001-07-13 |
| Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia (NCT00023920) | National Cancer Institute (NCI) | 2001-07-01 |
| STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia (NCT00015834) | National Cancer Institute (NCI) | 2001-05-01 |
| Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders (NCT02210858) | National Cancer Institute (NCI) | 2000-05-01 |
| Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia (NCT00006364) | National Cancer Institute (NCI) | 1999-11-01 |
| Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (NCT00003694) | National Cancer Institute (NCI) | 1999-03-01 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia (NCT00003145) | Fred Hutchinson Cancer Center | 1997-08-01 |